Dr. Federico on Risk Categorization in Neuroblastoma

Sara M. Federico, MD, discusses risk categorization in neuroblastoma.

Sara M. Federico, MD, an associate member of the St. Jude faculty at St. Jude Children’s Research Hospital, discusses risk categorization in neuroblastoma.

It is important to recognize the clear risk categorization in neuroblastoma, according to Federico. Historically, patients have been divided into low-, intermediate-, and high-risk disease categories, the criteria for which are primarily driven by age, and defined by less than 18 months old.

Additional criteria include disease stage, and the biology of the tumor, as well as factors such as amplification of MYCN, which is an oncogene amplification that occurs in approximately one-quarter of all patients with neuroblastoma and half of those with high-risk disease, Federico concludes.

Related Videos
Katherine B. Peters, MD, PhD
In this first episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, and Michael W. McDermott, MD, explain how low-intensity focused ultrasound works and the rationale for examining its use in cancer and other conditions.
Bently P. Doonan, MD
Jezabel Rodriguez-Blanco, PhD
Manmeet Singh Ahluwalia, MD
Navid Redjal, MD, FAANS, of Capital Health Cancer Center
Nader Sanai, MD
Related Content